Treatment of colorectal liver metastases.
BACKGROUND
Surgical resection is the only potentially curative treatment for colorectal liver metastases, with 5-year survival rates approaching 40 per cent. However, at present only 20-25 per cent of such lesions are deemed resectable. This review examines developments in neoadjuvant and adjuvant treatments of colorectal liver metastases that aim to improve the results of surgical management of this disease.


METHODS
A literature review was undertaken based on a Medline search from 1970 to May 1998.


RESULTS
Further evolution in surgical technique is unlikely to lead to a dramatic increase in the resectability rate of colorectal liver metastases. Recent developments in neoadjuvant and adjuvant chemotherapy schedules, together with a range of interventional radiological procedures and interstitial lytic techniques, show promise in terms of extending the limits of resectability and decreasing recurrence rates associated with these lesions. Using multimodality regimens 5-year survival rates of 40 per cent are now being reported for lesions that were initially considered irresectable.


CONCLUSIONS
Patients with colorectal liver metastases should be assessed in units that can offer all the specialist techniques necessary to deliver optimum care. Incorporation of newer neoadjuvant and adjuvant treatments into management strategies should occur in the setting of randomized trials.
Geoghegan
J G
JG
Klinikum der Friedrich Schiller Universität Jena, Abteilung für Allgemeine und Viszerale Chirurgie, Germany.
Scheele
J
J
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001918:Brachytherapy / Q000379:methods; D016461:Chemoembolization, Therapeutic / Q000379:methods; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms; D017679:Cryotherapy / Q000379:methods; D004621:Embolization, Therapeutic / Q000379:methods; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008113:Liver Neoplasms / Q000556:secondary / Q000628:therapy*
D000970:Antineoplastic Agents